Lantern Pharma Inc. - Common Stock (LTRN)

LTRN stock results show that Lantern Pharma beat analyst estimates for earnings per share the second quarter of 2024.

LTRN stock results show that Lantern Pharma missed analyst estimates for earnings per share the first quarter of 2024.

Keep an eye on machine learning stocks. With big demand, we could be looking at a half-trillion-dollar market by 2030.

No AI category went down in February, but 3 did in March - confirming my comment last week that

All but one of the 7 artificial intelligence stock categories that I analyze weekly increased in value this week. But two categories  are still down MTD, suggesting that the surge in the artificial intelligence technology sector is slowing. 

LTRN stock results show that Lantern Pharma beat analyst estimates for earnings per share the fourth quarter of 2023.

Companies Reporting Before The Bell • Niu Techs (NASDAQ:NIU) is expected to report earnings for its fourth quarter.

U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Wednesday.

Shares of United Natural Foods, Inc. (NYSE: UNFI) fell sharply during Wednesday’s session following second-quarter results.

Grand View Research says the global

Discover how these AI powerhouses are leveraging AI in the IT consulting, application software, and biotech industries.

The AI-powered drug discovery market is projected to grow at a 30% CAGR between now and 2030, with annual sales in excess of $50 billion anticipated. An AI drug discovery revolution is underway. 

With the promise of lower costs and shorter development timelines, AI-enabled drug discovery holds massive potential to increase the accessibility of drugs and to treat presently incurable conditions.